BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
NYSE:BIO • US0905722072
271.3 USD
-0.6 (-0.22%)
At close: Feb 20, 2026
271.3 USD
0 (0%)
After Hours: 2/20/2026, 8:18:49 PM
BIO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. While BIO has a great health rating, its profitability is only average at the moment. BIO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- BIO had positive earnings in the past year.
- In the past year BIO had a positive cash flow from operations.
- In the past 5 years BIO reported 4 times negative net income.
- BIO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -6.97%, BIO is in line with its industry, outperforming 51.72% of the companies in the same industry.
- The Return On Equity of BIO (-10.03%) is comparable to the rest of the industry.
- BIO's Return On Invested Capital of 2.26% is fine compared to the rest of the industry. BIO outperforms 62.07% of its industry peers.
- BIO had an Average Return On Invested Capital over the past 3 years of 2.69%. This is significantly below the industry average of 12.04%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- BIO's Operating Margin of 10.27% is fine compared to the rest of the industry. BIO outperforms 68.97% of its industry peers.
- In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
- BIO has a better Gross Margin (52.42%) than 62.07% of its industry peers.
- In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
- There is no outstanding debt for BIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 3.20 indicates that BIO is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.20, BIO is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
- BIO has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO would need 3.57 years to pay back of all of its debts.
- The Debt to FCF ratio of BIO (3.57) is better than 75.86% of its industry peers.
- BIO has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
- BIO has a Debt to Equity ratio of 0.18. This is comparable to the rest of the industry: BIO outperforms 56.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.2 |
ROIC/WACC0.21
WACC10.53%
2.3 Liquidity
- BIO has a Current Ratio of 5.44. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- BIO has a better Current ratio (5.44) than 84.48% of its industry peers.
- BIO has a Quick Ratio of 3.94. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 3.94, BIO is doing good in the industry, outperforming 67.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
- BIO shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.19% yearly.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
3.2 Future
- BIO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.38% yearly.
- BIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.60% yearly.
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue Next Year1.61%
Revenue Next 2Y2.36%
Revenue Next 3Y2.35%
Revenue Next 5Y1.6%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 27.35, which means the current valuation is very expensive for BIO.
- Based on the Price/Earnings ratio, BIO is valued a bit cheaper than the industry average as 65.52% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 26.99. BIO is around the same levels.
- The Price/Forward Earnings ratio is 26.47, which means the current valuation is very expensive for BIO.
- 67.24% of the companies in the same industry are more expensive than BIO, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, BIO is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.35 | ||
| Fwd PE | 26.47 |
4.2 Price Multiples
- BIO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BIO is cheaper than 81.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.73 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO does not grow enough to justify the current Price/Earnings ratio.
- BIO's earnings are expected to decrease with -3.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)8.2
PEG (5Y)N/A
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
5. Dividend
5.1 Amount
- No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
271.3
-0.6 (-0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners92.92%
Inst Owner Change1.78%
Ins Owners8.18%
Ins Owner Change0%
Market Cap7.32B
Revenue(TTM)N/A
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (33.47%)
Short Float %4.47%
Short Ratio3.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)14.15%
EPS NQ rev (1m)-1.46%
EPS NQ rev (3m)-4.14%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)-0.9%
Revenue NQ rev (1m)-0.65%
Revenue NQ rev (3m)-1.79%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.35 | ||
| Fwd PE | 26.47 | ||
| P/S | 2.86 | ||
| P/FCF | 21.73 | ||
| P/OCF | 14.89 | ||
| P/B | 1.09 | ||
| P/tB | 1.27 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.66%
EPS(NY)10.25
Fwd EY3.78%
FCF(TTM)12.48
FCFY4.6%
OCF(TTM)18.22
OCFY6.72%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)8.2
PEG (5Y)N/A
Graham Number236.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.2 |
F-Score5
WACC10.53%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
Revenue Next Year1.61%
Revenue Next 2Y2.36%
Revenue Next 3Y2.35%
Revenue Next 5Y1.6%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.36%
EBIT Next 3Y14.58%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 3.33% in the next year.